BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,135,054 | -33.3% | 721,831 | -20.0% | 0.71% | -23.3% |
| Q2 2023 | $73,693,891 | +22.2% | 902,780 | +11.1% | 0.93% | +9.9% |
| Q1 2023 | $60,295,272 | +88036.8% | 812,714 | -1.5% | 0.84% | -17.7% |
| Q4 2022 | $68,411 | -99.9% | 825,421 | +277.6% | 1.03% | +11.4% |
| Q3 2022 | $62,088,000 | -55.8% | 218,619 | -46.0% | 0.92% | -13.0% |
| Q2 2022 | $140,363,000 | +40.0% | 404,924 | +74.9% | 1.06% | -6.4% |
| Q1 2022 | $100,263,000 | -17.3% | 231,533 | -1.2% | 1.13% | -5.5% |
| Q4 2021 | $121,259,000 | +9.5% | 234,389 | +2.6% | 1.20% | +8.0% |
| Q3 2021 | $110,732,000 | +8.1% | 228,517 | +0.5% | 1.11% | +6.7% |
| Q2 2021 | $102,406,000 | +24.5% | 227,437 | +5.6% | 1.04% | +11.0% |
| Q1 2021 | $82,234,000 | -40.3% | 215,313 | -50.4% | 0.94% | -38.4% |
| Q4 2020 | $137,812,000 | +38.9% | 433,987 | +8.4% | 1.52% | +9.9% |
| Q3 2020 | $99,216,000 | -3.0% | 400,502 | +3.4% | 1.38% | -13.8% |
| Q2 2020 | $102,327,000 | +40.2% | 387,499 | +0.7% | 1.61% | +5.2% |
| Q1 2020 | $72,968,000 | -14.3% | 384,813 | -0.8% | 1.53% | -0.1% |
| Q4 2019 | $85,139,000 | +9.6% | 387,858 | -2.3% | 1.53% | +3.9% |
| Q3 2019 | $77,649,000 | -6.6% | 396,839 | -0.4% | 1.47% | -6.4% |
| Q2 2019 | $83,099,000 | -1.4% | 398,575 | -6.1% | 1.57% | -3.9% |
| Q1 2019 | $84,254,000 | +22.4% | 424,346 | -10.8% | 1.64% | +14.0% |
| Q4 2018 | $68,830,000 | -32.0% | 475,606 | -4.1% | 1.44% | -15.2% |
| Q3 2018 | $101,256,000 | +32.7% | 496,084 | -3.8% | 1.69% | +23.0% |
| Q2 2018 | $76,322,000 | -4.7% | 515,863 | -2.7% | 1.38% | -5.9% |
| Q1 2018 | $80,106,000 | +17.2% | 530,364 | +0.5% | 1.46% | +10.7% |
| Q4 2017 | $68,365,000 | +3.7% | 527,712 | -3.3% | 1.32% | +1.8% |
| Q3 2017 | $65,942,000 | -4.2% | 545,471 | -6.8% | 1.30% | -1.3% |
| Q2 2017 | $68,798,000 | +11.9% | 585,517 | -3.2% | 1.32% | +6.6% |
| Q1 2017 | $61,478,000 | -5.7% | 604,797 | -4.6% | 1.24% | -9.3% |
| Q4 2016 | $65,213,000 | -13.1% | 634,184 | -7.4% | 1.36% | -9.3% |
| Q3 2016 | $75,013,000 | -4.8% | 685,049 | -2.0% | 1.50% | -8.1% |
| Q2 2016 | $78,795,000 | +15.5% | 698,725 | -3.2% | 1.63% | +14.9% |
| Q1 2016 | $68,211,000 | +5.7% | 721,658 | +0.6% | 1.42% | +7.2% |
| Q4 2015 | $64,550,000 | -6.8% | 717,217 | -4.2% | 1.33% | -7.1% |
| Q3 2015 | $69,232,000 | -9.0% | 748,773 | -3.0% | 1.43% | -0.5% |
| Q2 2015 | $76,041,000 | -9.1% | 772,227 | -7.5% | 1.43% | -4.7% |
| Q1 2015 | $83,688,000 | +9.8% | 834,460 | +1.1% | 1.50% | +6.2% |
| Q4 2014 | $76,253,000 | -4.7% | 825,246 | -3.6% | 1.42% | -9.2% |
| Q3 2014 | $80,055,000 | – | 855,748 | – | 1.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |